

Submission Data File

General Information	
Form Type*	10-Q
Contact Name	Edgar Agents LLC
Contact Phone	732-780-5036
Filer File Number	
Filer CIK*	0001112372 (MEDICAL INTERNATIONAL TECHNOLOGY INC)
Filer CCC*	*****
Filer is Smaller Reporting Company	Yes
Confirming Copy	No
Notify via Website only	No
Return Copy	No
SROS*	NONE
Period*	06-30-2014
(End General Information)	

Document Information	
File Count*	9
Document Name 1*	f10q0614_medicalinter.htm
Document Type 1*	10-Q
Document Description 1	Quarterly Report
Document Name 2*	f10q0614ex31i_medicalinter.htm
Document Type 2*	EX-31.1
Document Description 2	Certification
Document Name 3*	f10q0614ex32i_medicalinter.htm
Document Type 3*	EX-32.1
Document Description 3	Certification
Document Name 4*	mdlh-20140630.xml
Document Type 4*	EX-101.INS
Document Description 4	XBRL Instance File
Document Name 5*	mdlh-20140630.xsd
Document Type 5*	EX-101.SCH
Document Description 5	XBRL Schema File
Document Name 6*	mdlh-20140630_cal.xml
Document Type 6*	EX-101.CAL
Document Description 6	XBRL Calculation File
Document Name 7*	mdlh-20140630_def.xml
Document Type 7*	EX-101.DEF
Document Description 7	XBRL Definition File
Document Name 8*	mdlh-20140630_lab.xml
Document Type 8*	EX-101.LAB
Document Description 8	XBRL Label File
Document Name 9*	mdlh-20140630_pre.xml
Document Type 9*	EX-101.PRE
Document Description 9	XBRL Presentation File
(End Document Information)	

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: **June 30, 2014**

Or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number: 000-31469

Medical International Technology, Inc.
(Exact name of registrant as specified in its charter)

Colorado

(State or other jurisdiction of
incorporation or organization)

84-1509950

(I.R.S. Employer
Identification No.)

1872 Beaulac, Ville Saint-Laurent
Montreal, Quebec, Canada HR4 2E9
(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: **(514) 339-9355**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer
(Do not check if a smaller reporting company)

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of shares outstanding of the registrant's common stock as of August 13, 2014 was 83,804,627.

MEDICAL INTERNATIONAL TECHNOLOGY, INC.

FORM 10-Q

June 30, 2014

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

<u>Item 1.</u>	<u>Consolidated Financial Statements</u>	3
	<u>Consolidated Balance Sheet</u>	3 – 4
	<u>Consolidated Statements of Operations</u>	5
	<u>Consolidated Statements of Cash Flows</u>	6
	<u>Consolidated Statements of Comprehensive Loss</u>	7
	<u>Consolidated Statement of Stockholders' (Deficit)</u>	8
	<u>Notes to Unaudited Consolidated Financial Statements</u>	9
<u>Item 2.</u>	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	14
<u>Item 3.</u>	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	17
<u>Item 4.</u>	<u>Controls and Procedures</u>	18
	<u>Part II. OTHER INFORMATION</u>	19
<u>Item 1.</u>	<u>Legal Proceedings</u>	19
<u>Item 1A.</u>	<u>Risk Factors</u>	19
<u>Item 2.</u>	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	19
<u>Item 3.</u>	<u>Defaults upon Senior Securities</u>	19
<u>Item 4.</u>	<u>Mine Safety Disclosures</u>	19
<u>Item 5.</u>	<u>Other Information</u>	19
<u>Item 6.</u>	<u>Exhibits</u>	19
	<u>SIGNATURES</u>	20

PART 1 - FINANCIAL INFORMATION

Item 1. Financial Information

CONSOLIDATED BALANCE SHEET

	June 30, 2014 <u>(Unaudited)</u>	September 30, 2013 <u>(Audited)</u>
Assets		
Current Assets		
Cash and cash equivalents	\$ 1,765	\$ 1,020
Accounts receivable	13,717	66,209
Inventories	290,142	293,693
Prepaid expenses	<u>5,672</u>	<u>33,730</u>
Total Current Assets	<u>311,296</u>	<u>394,652</u>
Long Term Investment		
Investment in MIT China Joint Venture	-	-
Property and Equipment		
Tooling and machinery	688,011	720,594
Furniture and office equipment	139,548	144,312
Leasehold improvements	<u>28,710</u>	<u>28,487</u>
	856,269	893,393
Less accumulated depreciation	(639,001)	(707,496)
Total property and equipment, net	217,268	185,897
Other Assets		
Patents (net of accumulated amortization of \$48,523 and \$25,303)	63,073	33,592
Total assets	<u>\$ 591,637</u>	<u>\$ 614,141</u>

The accompanying notes are an integral part of these consolidated financial statements.

CONSOLIDATED BALANCE SHEET

	<u>June 30,</u> <u>2014</u>	<u>September 30,</u> <u>2013</u>
	<u>(Unaudited)</u>	<u>(Audited)</u>
Liabilities and Stockholders' Equity (Deficit)		
Current Liabilities		
Bank line	\$ 74,976	\$ 63,200
Deferred income	7,991	-
Accounts payable and accrued expenses	129,475	121,944
Amounts due to related parties	20,000	-
Current portion of long term debts	<u>51,442</u>	<u>51,442</u>
	283,884	236,586
Long-Term Debts	<u>51,586</u>	<u>91,606</u>
Total Liabilities	<u>335,470</u>	<u>328,192</u>
Stockholders' Equity (Deficit)		
Preferred stock, \$.0001 par value; 3,000,000 shares authorized; No issued and outstanding shares	-	-
Common stock, \$.0001 par value; 100,000,000 shares authorized; 83,804,627 shares and 83,804,627 issued and outstanding, respectively	7,979	7,979
Additional paid-in capital	12,867,476	12,867,476
Deficit	(12,305,627)	(12,189,399)
Other comprehensive income (loss)	<u>(313,661)</u>	<u>(400,107)</u>
Total Stockholders' Equity (Deficit)	<u>256,167</u>	<u>285,949</u>
Total Liabilities and Stockholders' Equity (Deficit)	<u>\$ 591,637</u>	<u>\$ 614,141</u>

The accompanying notes are an integral part of these consolidated financial statements.

CONSOLIDATED STATEMENTS OF OPERATIONS

	Three-Months Period Ended June 30,		Nine-Months Period Ended June 30,	
	2014	2013	2014	2013
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Sales	\$ 152,436	\$ 238,158	\$ 299,280	\$ 528,310
Cost of sales	(35,913)	(97,307)	(86,563)	(166,897)
Gross profit (loss)	116,523	140,851	212,717	361,413
Selling, general, and administrative expenses	(147,963)	(336,492)	(320,240)	(540,371)
	(147,963)	(336,492)	(320,240)	(540,371)
Loss from operations	(31,440)	(195,641)	(107,523)	(178,958)
Other Income (Expense) Equity earnings (loss) on MIT China Joint Venture	-	(90,445)	-	(144,065)
Interest income/loss	297	539	1,246	760
Interest expense	(4,282)	(5,997)	(9,951)	(11,521)
	(3,985)	(95,903)	(8,705)	(154,826)
Net Loss	\$ (35,425)	\$ (291,544)	\$ (116,228)	\$ (333,784)
Basic (loss) per share	\$ (0.0004)	\$ (0.003)	\$ (0.001)	\$ (0.004)
Basic weighted average shares outstanding	83,804,627	83,804,627	83,804,627	83,804,627

The accompanying notes are an integral part of these consolidated financial statements.

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Nine-Month Period Ended	
	June 30, 2014	June 30, 2013
Cash flows from operating activities:		
Net loss	\$ (116,228)	\$ (333,785)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:		
Equity loss from MIT China Joint Venture	—	144,065
Depreciation and amortization expense	63,519	94,880
Related party payables settle by common stock	20,000	—
Capitalization of related party debts		
Changes in:		
Accounts receivable	52,492	19,080
Inventories	3,551	9,493
Prepaid expenses	28,057	11,377
Accounts payable and accrued liabilities	7,530	5,900
Deferred income	7,991	(109,479)
Net cash provided (used) by operating activities	<u>66,912</u>	<u>(158,469)</u>
Cash flows from investing activities:		
Acquisition of patents	(6,369)	(5,251)
Net cash used by investing activities	<u>(6,369)</u>	<u>(5,251)</u>
Cash flows from financing activities:		
Bank line	11,776	(92,147)
Bank loans	(40,020)	(48,226)
Net cash used by financing activities	<u>(28,224)</u>	<u>(132,367)</u>
Effect of exchange rates	(31,554)	8,487
Increase (decrease) in cash	745	(295,606)
Cash, beginning of period	1,020	303,497
Cash, end of period	<u>\$ 1,765</u>	<u>\$ 7,981</u>
Supplemental disclosure of cash flow information:		
Cash paid for interest	\$ 9,952	\$ 10,762
Cash paid for federal income taxes	<u>\$ —</u>	<u>\$ —</u>

The accompanying notes are an integral part of these consolidated financial statements.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

	Nine Months Ended June 30, 2014	Nine Months Ended June 30, 2013
Net loss	\$ (116,228)	\$ (333,784)
Other comprehensive income (loss)		
Foreign currency translation adjustment	<u>86,446</u>	<u>(12,107)</u>
Net comprehensive loss	<u>\$ (29,782)</u>	<u>\$ (345,891)</u>

The accompanying notes are an integral part of these consolidated financial statements

CONSOLIDATED STATEMENT OF STOCKHOLDERS' (DEFICIT)

	Common Stock		Additional Paid in	
	Shares	Amount	Capital	Deficit
Balance – September 30, 2013	83,804,627	\$ 7,979	\$ 12,867,386	\$ (12,189,399)
Shares issued for debts	-	-	-	-
Shares issued for services	-	-	-	-
Shares issued for additional capital	-	-	-	-
Net loss for the nine month ended June 30, 2014	-	-	-	(116,228)
Balance – June 30, 2014	<u>83,894,627</u>	<u>7,979</u>	<u>12,867,386</u>	<u>(12,305,627)</u>

The accompanying notes are an integral part of these consolidated financial statements

Notes to Financial Statements

(Unaudited)

Note 1 – Basis of Presentation

Interim Financial Statements

The accompanying unaudited condensed consolidated financial statements of Medical International Technology, Inc. (“MIT” or the “Company”) and its subsidiary (collectively referred to as the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America, pursuant to the rules and regulations of the Securities and Exchange Commission. All significant intercompany balances and transactions have been eliminated. These financial statements do not include all information and notes required by accounting principles generally accepted in the United States of America for complete financial statements. It is recommended that these interim unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2013.

In the opinion of management, all adjustments (consisting only of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine month periods ended June 30, 2014 are not necessarily indicative of the results which may be expected for any other interim periods or for the year ending September 30, 2014. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Note 2 – Inventories

Inventories at June 30, 2014 and September 30, 2013 consist of the following:

	<u>June 30, 2014</u>	<u>September 30, 2013</u>
Raw materials	\$ 213,455	\$ 216,053
Work in process	66,294	66,858
Finished goods	10,393	10,782
Total	<u>\$ 290,142</u>	<u>\$ 293,693</u>

Note 3 – Property and Equipment

The cost of property and equipment is depreciated over the estimated useful lives of the related assets, which range from 5 to 7 years. Depreciation is computed on the straight-line method for financial reporting purposes and on the declining balance method for income tax reporting purposes. Depreciation expense for the nine months ended June 30, 2014 and 2013 was \$48,523 and \$84,730, respectively

Note 4 – Intangible Assets

As of June 30, 2014 the Company has net patents on certain technologies aggregating \$63,073. Amortization expense for the nine months ended June 30, 2014 and 2013 was \$14,996 and \$10,149, respectively. During the nine months ended June 30, 2014, the Company capitalized patent costs on its needle-free injector of \$34,831. Following is a detail of patents at June 30, 2014.

	<u>Gross Intangible Assets</u>	<u>Accumulated Amortization</u>	<u>Net Intangible Assets</u>	<u>Weighted Average Life (Years)</u>
Patents	\$ 99,976	\$ 36,903	\$ 63,073	7.5 through 15

Notes to Financial Statements

(Unaudited)

Note 5 – Joint venture agreement

On May 6, 2009, the Company entered into a certain joint venture agreement (the “Joint Venture Agreement”) with Jiangsu Hualan Biotechnology Ltd. (China) (“Jiangsu Hualan”). Pursuant to the Joint Venture Agreement, the parties thereto established a joint venture company, Jiangsu Hualan MIT Medical Technology (MIT China) Ltd. (“MIT China” or the “Joint Venture”), focusing on research, production and sales of medical equipments, import and export of medical equipments and components products, especially Needle-Free Jet Injector products. The total investment by the Joint Venture shall amount to \$2,000,000, and the registered capital shall amount to \$1,400,000. The Company invested cash of \$426,678 and transferred the license rights to produce and sell the Company’s needle-free injectors products into the Joint Venture. The license rights were valued at \$280,000 under the agreement. The contributions by the Company resulted in the Company owning 49% of the registered capital of the Joint Venture. Jiangsu Hualan contributed cash of \$714,000, and owns 51% of the registered capital.

Under the Joint Venture Agreement, the Company appointed 1 member, and Jiangsu Hualan appointed 2 members, to the board of directors of the Joint Venture. Profits of the Joint Venture will be allocated based upon each party’s investment in the registered capital.

In March 2012, MIT China agreed and sold 9% of the joint venture for an investment of 18,000,000 RMB (US\$3,000,000). Jiangsu Hualan now has 46.41%, the Company has 44.59%, and Taizhou Amazon Investment Center has 9% ownership in the MIT China joint venture.

The Company accounts for its investment in MIT China in accordance with Financial Accounting Standards Board Accounting Standards Codification 323, “Investment — Equity Method and Joint Venture” (ASC 323), previously referred to as Accounting Principles Board Opinion No. 18, “The Equity Method of Accounting for Investments in Common Stock.” Accordingly, the Company adjusts the carrying amount of its investment in MIT China to recognize its share of earnings or losses. As of June 30, 2014 and September 30, 2013, the Company’s had no recorded investment remaining in the MIT China.

Note 6 – Bank Line

The Company, through a hypothec agreement, has a line of credit up to a maximum of \$100,000. The line is secured by Investissement Quebec (a Quebec government entity), by Karim Menassa (personally) and by account receivables, inventories, equipment and all other assets of the Company. At June 30, 2014 and September 30, 2013, the Company had \$74,980 and \$63,200 outstanding under the agreement.

Note 7 – Related Party Transactions

Related party balances consist of the following at June 30, 2014 and September 30, 2013:

	June 30, 2014	September 30, 2013
Payable to 9211-0766 Quebec Inc	<u>20,000</u>	<u>-</u>
	<u>\$ 20,000</u>	<u>\$ -</u>

The Company has borrowed from shareholders and corporations owned by shareholders. These loans are bearing interest at 8%, and are due during fiscal 2014.

Notes to Financial Statements

(Unaudited)

Note 8 – Stockholders' Equity (Deficit)

Issuance of Common Stock

From time to time, the Company will issue common stock for services rendered, debt reductions or as part of private placement offerings.

For the three and nine months ended June 30, 2014, there were no common stock issuances.

Preferred Stock

As of June 30, 2014, there was no preferred stock outstanding. Dividend features and voting rights are at the discretion of the Board of Directors without the requirement of shareholder approval.

Outstanding Options and Warrants

As of June 30, 2014 and September 30, 2013, there are no options or warrants outstanding to purchase shares of the Company's common stock.

Note 9 –Operating Leases

The Company leases its office and warehouse space under an operating lease that expires on December 31, 2014 that calls for a monthly rent of \$4, 250. Rent expense for the nine months ended June 30, 2014 was approximately 36,000.

Notes to Financial Statements

(Unaudited)

Note 10 –Notes Payable

Long-term debt consists of the following at June 30, 2014 and September 30, 2013:

	<u>June 30, 2014</u>	<u>September 30, 2013</u>
Note payable to a bank, bearing interest at prime plus 3%, secured by equipment, due June 21, 2016.	\$ 65,274	\$ 89,194
Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) Equal and consecutive quarterly installment starting twelve (12) month after the project completion date.	37,754	53,854
Total long-term debt	<u>103,028</u>	<u>143,048</u>
Current portion of long-term debt	<u>(51,442)</u>	<u>(51,442)</u>
Long-term debt, net of current portion	<u>\$ 51,586</u>	<u>\$ 91,606</u>

Notes to Financial Statements

(Unaudited)

Future scheduled principal payments under note agreements are as follows:

Year ended

June 30, 2015	51,442
June 30, 2016	144
	<u>\$ 51,586</u>

Note 11 – Contingencies

Legal Proceedings

We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries' officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following plan of operation provides information which management believes is relevant to an assessment and understanding of our results of operations and financial condition. The discussion should be read along with our financial statements and notes thereto. This section includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.

Business Development

Expanding the product line:

Medical International Technology Inc. ("MIT or the "Company") has been expanding financial resources in R&D in the last 5 years. MIT already has 5 products for the human market and 9 products for the animal market. The Company will soon be unveiling two new additions to its human product line and one for its animal line.

MIT's patented technology has received approval in several countries worldwide. The Company expects that the three new products will be no exception.

The Company is refocusing its efforts and will target FDA approval for two of its latest product lines: first, the home use injector for diabetics and other treatments requiring daily injections, and second, product targeting physicians in their clinics for vaccination and other biological injection medications. FDA approval for these two products will help the Company's credibility all over the world.

MIT products pipeline is already defined for 2012/2013; the realization of these new products design will be achieved by new finance to MIT and or a partnership with Medical and Pharmaceutical Companies.

Diabetes

The Company intends to target diabetes market through its newly developed Med-Jet model MIT-P-I within the next 8 to 10 months. MIT intends to first introduce this product in China in order to grow its production capacity to eventually expand into other countries. The Med-Jet MIT-P-I is designed to be safe, precise, accurate, effective, easy to use and friendly to the environment.

Dentistry

The Company plans to target the potentially lucrative dental Anesthesia market with its Med-Jet model MIT-H-VI within the next 12 to 16 months. MIT intends to introduce this new product in North America first before being introduced into other markets.

Poultry Vaccinations

MIT's newly designed Agro-Jet model MIT-XII will help prevent the spread of deadly diseases by providing a needle-free alternative to the vaccination of billions of day-old baby chicks yearly. This high speed vaccinator will be able to inject thousands of birds per hour safely, precisely, accurately, effectively, with ease of use and friendly to the environment.

Projected Sales and Market Breakdown

The following information will outline market expectations by category and timeframe:

Human applications:

In the next fiscal year, the Company plans to expand its market for cosmetic dermatology, plastic surgery, and general practitioner for single and mass injections. It will do so through the use of the Med-Jet models MIT MBX and MIT-H-III. The Company also plans to introduce a model MESO-JET a product for the injections on the face for all cosmetic dermatology procedures, as well as the MIT-H-IV-1 and MIT-H-IV-5, the MIT P-I injector for Diabetics, , and the MIT-H-VI Dental injector.

Animal applications:

In the next fiscal year, the Company plans to expand into the pork, cattle, and poultry markets, using our existing and newly redesigned products for mass animal vaccination.

China Joint Venture

The creation of MIT China in June of 2009 has given MIT a unique advantage to expand its production operations and increase its sales and profits in the multi-billion dollar worldwide needle-free injector market. Furthermore, MIT China venture will help MIT supply large production volumes in lesser time, which will attract large medical and pharmaceutical partners.

The introduction of our Agro-Jet needle-free injector for animal application is progressing well; our veterinary staff has been successfully job training our distributors in various regions. We expect that these efforts will result in sales growth for the coming fiscal quarters and years.

During the third quarter of fiscal year 2011, MIT China purchased 151,000 sq. ft. of land and began construction of their first building in Taizhou (China Medical City). This first building of 40,000 sq. ft. when finalized will be used for the production of injectors for the Chinese market only.

The work in progress at MIT China for the construction of its 40,000 sq. ft. building is expected to be completed and certified by the Chinese SFDA by March 2014. We will start planning and purchasing much of the equipment and tools necessary for the assembly and production of some of our Agro-Jet and Med-Jet products. The production facility should be able to supply a large number of injectors and disposables to the Chinese market.

Per the recent discussions and understanding of our general manager, Ethan Sun, with our Joint Venture partner, our plan of sales and expansion into the Chinese market is progressing and MIT China agreed and sold 9% of their joint venture for an investment of 18,000,000 RMB (US\$3,000,000). MIT China now has 46.41%, we have 44.59%, and Taizhou Amazon Investment Center has 9% ownership in such venture.

Our objective is to ensure that our injectors become an indispensable and environmentally friendly product for doctors, dentists, veterinarians and home users around the world.

We will continue providing a safe and effective means to help prevent the spread of deadly diseases to both humans and animals through the use of the Med-Jet® and Agro-Jet® needle-free injection system.

Results of Operations

Results of Operations for the three months ended June 30, 2014 and 2013

For the three-month period ended June 30, 2014 the Company experienced a net loss from operations of (\$35,425) which was primarily due to selling, general and administrative expenses of \$147,963 and sales of \$152,436. Gross profits for the period were \$116,523.

For the three-month period ended June 30, 2013 the Company experienced a net loss from operations of \$ (195,641) which was primarily due to selling, general and administrative expenses of \$336,492 and sales of \$238,158. Gross profits for the period were \$140,851.

The reduced net loss between the comparable quarters was due to higher sales prices of our systems better control on the operational and administration expenses, as the Company continues to push its products into the market along with reduced research and development costs. Sales for the three-month period ending June 30, 2014 were \$152,436 compared to sales of \$238,158 for the same period last year. Gross profits for the period ending June 30, 2014 represented 76% of sales, where gross profits for the same period last year represented 59% of sales.

Results of Operations for the nine months ended June 30, 2014 and 2013

For the nine-month period ended June 30, 2014 the Company experienced a net loss of (\$116,228) which was primarily due to selling, general and administrative expenses of \$320,240. Gross profits for the period were \$212,712.

For the nine-month period ended June 30, 2013 the Company experienced a net loss from operations of (\$178,958) which was primarily due to selling, general and administrative expenses of \$437,758. Gross profits for the period were \$282,262.

The reduced net loss between the comparable quarters was due to higher sales prices of our systems better control on the operational and administration expenses, as the Company continues to push its products into the market along with reduced research and development costs. Sales for the nine-month period ending March 31, 2014 were \$299,280 compared to sales of \$528,310 for the same period last year. Gross profits for the period ending June 30, 2014 represented 71% of sales, where gross profits for the same period last year represented 53% of sales.

Liquidity and Capital Resources

For the nine-month period ending June 30, 2014, the Company's cash position, including access to cash through a revolving line of credit, increased by \$745. Net cash used in operating activities was \$66,912. Cash used by financing activities was \$28,224 which was primarily a result of bank loans of \$40,020. Cash used by investing activities was \$6,369, which was a result of acquisitions of new patent rights. The effect of exchange rates on cash decreased cash balances by \$31,554.

For the nine-month period ending June 30, 2013, the Company's cash position, including access to cash through a revolving line of credit, decreased to \$295,606. Net cash used in operating activities was \$86,453. Cash used by financing activities was \$140,373 which was primarily a result of bank line of \$92,147. Cash used by investing activities was \$5,251, which was a result of acquisitions of new patent rights. The effect of exchange rates on cash increased cash balances by \$8,487.

Plan of Operations

MIT intends to concentrate its activities in the medical and veterinary sectors, in particular, in the field of equipment and instrumentation. The Company's strategy is to build good, reliable and cost effective products, seek and establish strategic alliances with different pharmaceutical companies and manufacturers to ensure good distribution channels for its products.

MIT promotes and sells products in over 30 countries including the United States of America. MIT is exerting every effort and using its resources to promote its products and to open markets for its technology. As we continue to market our products, we hope to gain broader acceptance of the needle-free injection technology. MIT is continually researching and developing its products to the market needs.

We will continue to seek additional funding to expand operations, develop sales revenue, conduct presentation to medical and pharmaceutical companies, achieve sales to a volume sufficient to sustain operations and yield a good return to our shareholders.

Product Development

Per our previous filings for FDA approval for our needle-free injector, the MED-JET is designed specifically for mass human inoculations. The MED-JET is capable of delivering many types of medications such as vaccines, insulin and other types of injectables. Its low-pressure technology offers an advantage to alternative high pressure systems that can cause blowbacks and expose medical workers and patients alike to microscopic traces of blood.

According to the International Sharps Injury Prevention Society (<http://www.isips.org>), it has been estimated that one out of every seven workers is accidentally struck by a contaminated sharp point each and every year. The Center for Disease Control (CDC: <http://www.cdc.gov/niosh/2000-108.html#5>) estimates that there are 600,000 to 800,000 needle stick injuries per year in the U.S. alone, and many are not reported. More than 20 types of infectious agents have been transmitted through needlesticks, including hepatitis B and C, tuberculosis, syphilis, malaria, herpes, diphtheria, gonorrhea, typhus and Rocky Mountain spotted fever. The MED-JET will eliminate this risk to health care professionals and create a safer workplace. Other advantages include its light weight (0.5 kg) and an excellent medication absorption rate. Additionally, the system has the ability to increase or decrease the volume and pressure of injection. This technology is unique to MIT's MED-JET MBX Injector. The system is designed to inject up to 600 individuals an hour.

The approval process can be expensive and may take an extended period of time. There can be no assurance that this system will receive approval from the FDA or if approved gain broad acceptance by the medical community or individual patients.

During the last quarter of 2011 we signed with an outside consultant to help MIT with the FDA approval process and to expedite the approval. This work is proceeding and few more tests must be done in order to file complete documentations to FDA, we have completed all the tests and we have already filled the application, we should now expect a communication from FDA within the next three month.

On December 15, 2005, we received full certification granted under the International Organization for Standardization, as well as the Canadian Medical Device Conformity Assessment System for devices to be licensed by HEALTH CANADA. These certifications allow MIT to currently market the Med-Jet Needle-Free Injector for human use in all countries other than the U.S. The Med-Jet injector has been submitted for FDA approval which, if accepted, will allow MIT to sell the Med-Jet in the United States, making it a truly worldwide system.

MIT's Needle-Free Injection System, designed specifically to allow fast, accurate and safe injections, is rapidly moving toward establishing itself as a valuable instrument in the fight against disease in both humans and animals. Spurred on by growing fears of a worldwide epidemic that could match or even exceed the deadly flu pandemic of 1918 which killed millions of people, the MIT team is focusing its efforts to make its Needle-Free Injection System available to the world.

MIT will increasingly promote its Agro-Jet needle-free injector. Having the same benefits as Med-Jet, Agro-Jet will become a valuable instrument in the fight against Avian Flu via its ability to mass inoculate animals at over 1000 injections per hour.

Off Balance Sheet Arrangements

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to our stockholders.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not required for Smaller Reporting Companies.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 (“Exchange Act”), the Company carried out an evaluation, with the participation of the Company’s management, including the Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”) (the Company’s principal financial and accounting officer), of the effectiveness of the Company’s disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Company’s CEO and CFO concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including the Company’s CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the quarter covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

Item 1. Legal Proceedings

We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries' officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

Item 1A. Risk Factors

Not required for Smaller Reporting Companies.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other information

None.

Item 6. Exhibits

Exhibits

31.1	Certification of Principal Executive Officer and Principal Financial Officer of the Registrant pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 *	Certification of Principal Executive Officer and Principal Financial Officer of the Registrant pursuant to 18U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS **	XBRL Instance Document
101.SCH **	XBRL Taxonomy Schema
101.CAL **	XBRL Taxonomy Calculation Linkbase
101.DEF **	XBRL Taxonomy Definition Linkbase
101.LAB **	XBRL Taxonomy Label Linkbase
101.PRE **	XBRL Taxonomy Presentation Linkbase

*In accordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed.

** Furnished herewith. XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 13, 2014

Medical International Technology, Inc.

By: /s/ Karim Menassa
Karim Menassa
President, Chief Executive Officer, and
Chief Financial Officer
(Duly Authorized Officer, Principal Executive Officer,
and Principal Financial Officer)

**CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER AND
PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002**

I, Karim Menassa, certify that:

1. I have reviewed this Form 10-Q of Medical International Technology, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principals;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financing reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

Date: August 13, 2014

/s/ Karim Menassa
Karim Menassa
President and Chief Executive Officer,
Chief Financial Officer, interim Secretary
(Principal Executive and Principal Financial Officer)

**CERTIFICATION OF
PRINCIPAL EXECUTIVE OFFICER
AND
PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350**

In connection with the accompanying quarterly report on Form 10-Q of Medical International Technology, Inc. for the period ending June 30, 2014, I, Karim Menassa, Principal Executive Officer and Principal Financial Officer of Medical International Technology, Inc., hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge and belief, that:

1. Such quarterly report on Form 10-Q for the period ending June 30, 2014, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in such quarterly report of Form 10-Q for the period ending June 30, 2014, fairly represents in all material respects, the financial condition and results of operations of Medical International Technology, Inc.

Date: August 13th, 2014

MEDICAL INTERNATIONAL TECHNOLOGY, INC.

/s/ Karim Menassa

Karim Menassa
President and Chief Executive Officer,
Chief Financial Officer, interim Secretary
(Principal Executive and Principal Financial Officer)